Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update Life Science Investing News
Jamieson Wellness Inc. Announces Date of First Quarter 2024 Financial Results and Conference Call Pharmaceutical Investing
New Novartis Fabhalta® data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy Pharmaceutical Investing
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029 Pharmaceutical Investing
Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Pharmaceutical Investing
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer Life Science Investing News
